Take charge of your COVID-19 testing program
Social distancing, hand washing, vaccines, and mask wearing are best practices for minimizing the spread of COVID-19. Testing is another powerful tool to give the reassurance you need to resume a more robust schedule.
The BinaxNOW™ COVID-19 Ag Card is a fast, reliable and affordable antigen test that uses a simple nasal swab. It requires no instrumentation and gives results in just 15 minutes.
The NAVICA system is a comprehensive platform for supporting your COVID-19 testing program that works seamlessly with the BinaxNOW COVID-19 test. It features easy-to-use apps for your employees, administrators, and management, and it includes ancillary state reporting capabilities.
Individuals use this mobile app to display their NAVICA ID when getting tested, and to view and share results from select Abbott rapid COVID-19 tests.* The app is available at no charge on the App Store™ and Google Play®.
Organization use this web portal to help manage testing sites that administer Abbott rapid COVID-19 tests, manage testing populations (such as who gets tested and how often) and monitor test results.**
Testing sites use this tablet app to provide results from select Abbott rapid COVID-19 tests directly to consumers through the NAVICA Consumer App.
*A negative test result will generate a digitally encrypted NAVICA Pass, similar to an airline boarding pass. NAVICA-enabled organizations will be able to verify an individual's negative COVID-19 test result by scanning the NAVICA Pass to facilitate entry into organizations.
**The NAVICA Connect Portal includes an option to report all COVID-19 test results to state authorities.
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Based on your current location, the content on this page may not be relevant for your country.